PARP inhibitors as radiosensitizers: a comprehensive review of preclinical evidence and clinical applications

Poly (ADP ribose) polymerase 1 (PARP1) plays a central role in the response of DNA damage induced by tumor radiotherapy. This paper systematically reviewed the structural and functional characteristics of PARP1 and its molecular mechanism in DNA damage repair, and focused on the preclinical evidence and clinical transformation research progress of PARP inhibitor (parpi) as a radiosensitizer. PARP1 affects the effect of radiotherapy by recognizing DNA breakage, catalyzing par modification and regulating repair pathway, while parpi significantly enhances radiosensitivity by inhibiting DNA repair, inducing synthetic lethal effect and regulating immune microenvironment. Although preclinical studies have shown good prospects in a variety of solid tumors, clinical transformation still faces challenges such as heterogeneity of efficacy and drug resistance mechanism. Future research should focus on precise treatment strategies, joint scheme optimization and drug resistance mechanism exploration, so as to promote the wide application of parpi in radiotherapy. This article presents a narrative review of the preclinical and clinical evidence supporting the use of PARP inhibitors as radiosensitizers.

• Publication year

  2025

• Venue

  Frontiers in Oncology

• Publication date

  2025-11-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fonc.2025.1702121PMID 41367875PMCID 12682679
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer

  2025cited by this paper
• XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites

  2025cited by this paper
• Distinct regulation of ATM signaling by DNA single-strand breaks and APE1

  2024cited by this paper
• Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal

  2024cited by this paper
• Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

  2024cited by this paper
• Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

  2023cited by this paper
• In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib

  2023cited by this paper
• First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

  2023cited by this paper
• Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

  2023cited by this paper
• PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.

  2023cited by this paper
• Regulation of PARP1 and its apoptotic variant activity by single‐stranded DNA

  2023cited by this paper
• Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.

  2022cited by this paper
• Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.

  2022cited by this paper
• Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

  2022cited by this paper
• Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis

  2022cited by this paper
• Immediate-Early, Early, and Late Responses to DNA Double Stranded Breaks

  2022cited by this paper
• A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).

  2021cited by this paper
• Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.

  2021cited by this paper
• PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway.

  2021cited by this paper
• Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.

  2021cited by this paper
• Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

  2021cited by this paper
• Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.

  2021cited by this paper
• Combination of Olaparib with radiotherapy for triple‐negative breast cancers: One‐year toxicity report of the RADIOPARP Phase I trial

  2021cited by this paper
• A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study

  2021cited by this paper
• Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

  2021cited by this paper
• PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells

  2020cited by this paper
• Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma

  2020influential reference
• Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

  2020cited by this paper
• Combination of Olaparib and radiotherapy for triple negative breast cancer: preliminary results of the RADIOPARP phase I trial.

  2020cited by this paper
• Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models

  2020cited by this paper
• Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

  2020cited by this paper
• DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

  2020cited by this paper
• Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells

  2020cited by this paper
• Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma

  2020cited by this paper
• A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study.

  2020cited by this paper
• PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers

  2019cited by this paper
• PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation

  2019cited by this paper
• Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

  2019cited by this paper
• Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand

  2019cited by this paper
• Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

  2019cited by this paper
• A functional ex vivo assay to detect PARP1‐EJ repair and radiosensitization by PARP‐inhibitor in prostate cancer

  2019cited by this paper
• Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer

  2018cited by this paper
• Cancer Radiosensitizers.

  2018cited by this paper
• Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

  2018cited by this paper
• Olaparib nanoparticles potentiated radiosensitization effects on lung cancer

  2018cited by this paper
• PARP inhibitors: Synthetic lethality in the clinic

  2017cited by this paper
• ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells

  2017cited by this paper
• Coordination of DNA single strand break repair.

  2017cited by this paper
• Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.

  2017cited by this paper
• PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

  2016influential reference
• Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality

  2016cited by this paper
• PARP抑制剂对Lewis肺癌细胞及移植瘤放疗增敏作用及其机制

  2016cited by this paper
• Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition

  2016cited by this paper
• Replication Fork Stability Confers Chemoresistance in BRCA-deficient Cells

  2016cited by this paper
• Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models

  2016cited by this paper
• SLFN11 inhibits checkpoint maintenance and homologous recombination repair

  2015cited by this paper
• Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

  2015cited by this paper
• Radiation Induced DNA Double-Strand Breaks in Radiology

  2015cited by this paper
• Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer

  2015influential reference
• Inhibition of PARP1‐dependent end‐joining contributes to Olaparib‐mediated radiosensitization in tumor cells

  2014cited by this paper
• Past, present, and future of radiotherapy for the benefit of patients

  2013cited by this paper
• Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

  2013cited by this paper
• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2013cited by this paper
• The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport.

  2012cited by this paper
• The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks

  2012cited by this paper
• Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation

  2011cited by this paper
• A review of PARP inhibitors: from bench to bedside.

  2011cited by this paper
• Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

  2011influential reference
• The DNA-Binding Domain of Human PARP-1 Interacts with DNA Single-Strand Breaks as a Monomer through Its Second Zinc Finger

  2011cited by this paper
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• Parp1-XRCC1 and the repair of DNA double strand breaks in mouse round spermatids.

  2010cited by this paper
• Apurinic/apyrimidinic (AP) site recognition by the 5′-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1)

  2010cited by this paper
• Identification and SAR of Novel Pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives as Inhibitors of Poly(ADP-Ribose) Polymerase-1 (PARP-1).

  2010cited by this paper
• In vitro and In vivo Radiosensitization of Glioblastoma Cells by the Poly (ADP-Ribose) Polymerase Inhibitor E7016

  2009cited by this paper
• Parthanatos, a messenger of death.

  2009cited by this paper
• Head and neck cancer radiosensitization by the novel poly(ADP‐ribose) polymerase inhibitor GPI‐15427

  2009cited by this paper
• Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation.

  2008cited by this paper
• Domain C of human poly(ADP-ribose) polymerase-1 is important for enzyme activity and contains a novel zinc-ribbon motif.

  2008cited by this paper
• A Third Zinc-binding Domain of Human Poly(ADP-ribose) Polymerase-1 Coordinates DNA-dependent Enzyme Activation*

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Poly ADP-ribose polymerase-1: an international molecule of mystery.

  2008cited by this paper
• Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.

  2007cited by this paper
• Regulation of Poly(ADP-ribose) Polymerase-1 by DNA Structure-specific Binding*

  2005cited by this paper
• A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage.

  2003cited by this paper
• Transcriptional Down-regulation of Poly(ADP-ribose) Polymerase Gene Expression by E1A Binding to pRb Proteins Protects Murine Keratinocytes from Radiation-induced Apoptosis*

  1999cited by this paper
• Human poly(ADP-ribose) polymerase gene. Cloning of the promoter region.

  1990cited by this paper
• Human Nuclear NAD+ ADP-Ribosyltransferase(polymerizing): Organization of the Gene

  1989cited by this paper
• cDNA sequence, protein structure, and chromosomal location of the human gene for poly(ADP-ribose) polymerase.

  1987cited by this paper
• Primary structure of human poly(ADP-ribose) synthetase as deduced from cDNA sequence.

  1987cited by this paper
• Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks.

  1980cited by this paper

• No citing papers are available for this paper.